title: Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).
authors: Ricardo
authors: R
authors: García-Muñoz
authors: Alicia
authors: A
authors: Galar
authors: Cristina
authors: C
authors: Moreno
authors: Paula
authors: P
authors: Rodríguez-Otero
authors: Elena
authors: E
authors: Panizo-Morgado
authors: Mariano
authors: M
authors: Ponz-Sarvisê
authors: Mirian
authors: M
authors: Fernandez-Alonso
authors: Manuel
authors: M
authors: Rubio
authors: Juana
authors: J
authors: Merino
authors: Braulia
authors: B
authors: Cuesta
authors: Carlos
authors: C
authors: Panizol
authors: Felipe
authors: F
authors: Prosper
mesh_terms: D000208:Acute Disease; D003587:Cytomegalovirus / Q000502:physiology*; D000069439:Dasatinib; D005260:Female; D015654:Herpesvirus 6, Human / Q000502:physiology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000209:etiology*; D016732:Parvovirus B19, Human; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib